INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Spectrum Pharmaceuticals, Inc. & Urges Investors to Contact the ...
December 09 2015 - 7:40PM
Business Wire
Lundin Law PC announces it is investigating claims against
Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”)
(Nasdaq: SPPI) concerning possible violations of federal securities
laws. The investigation is related to allegations that certain
statements issued by Spectrum were false and misleading concerning
the Company’s financial performance.
To participate in this class action lawsuit, please contact
Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via
e-mail at brian@lundinlawpc.com.
On October 23, 2015, Spectrum announced that it had received a
Complete Response Letter from the U.S. Food and Drug Administration
(FDA) in response to its New Drug Application seeking clearance for
Evomela, indicating that the FDA cannot approve the application in
its present form. When the truth was revealed, shares dropped,
causing investors harm.
No class has been certified in the above action. Until a class
is certified, you are not considered represented by an attorney.
You may also choose to do nothing and be an absent class
member.
Lundin Law PC was created by Brian Lundin, a securities
litigator based in Los Angeles.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151209006604/en/
Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile:
888-713-1125brian@lundinlaw.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Sep 2023 to Sep 2024